ExpreS2ion Biotechnologies offers unrivalled expertise with the Drosophila S2 expression system, and biopharmaceutical proteins can be produced at competitive cost with the system. Using our system of vectors, optimised medium and S2 cells, up to ten fold increases in protein production can be achieved compared to currently available methods for S2 expression. The ExpreS2 expression system is applicable for the production of pharmaceutical proteins in cases where authentic protein structure, mammalian-like glycosylation, and high protein yields are required in a timely and cost-effective manner.
The key components of our proprietary S2 system provide an integrated platform that facilitates uptake at all levels of protein production needs, from early research to GMP manufacture for clinical or commercial purposes.
These proprietary components include:
Together, these components constitute the ExpreS2 expression system. Each component is superior to already existing commercially available components in terms of yield, reproducibility and robustness. The package offers a market leading protein expression system for production of biopharmaceuticals. The expression package offers ease of use, high success rate, consistent high yields, reproducibility, up-scalability, cost- and time savings, and compliance with cGMP and regulatory requirements. Furthermore, ExpreS2ion Biotechnologies also offers an expert service package (cell line development, cell banking, etc.) to facilitate transfer to our collaboration partners for clinical and commercial production.